Wason

Improving the analysis of composite endpoints in rare disease trials

*Orphanet Journal of Rare Diseases* 2018; 13:81

An optimised multi-arm multi-stage clinical trial design for unknown variance

*Contemporary Clinical Trials* 2018; 67:116-120

Response‐adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?

*Pharmaceutical Statistics* 2018; 17(2):182-197

Adaptive designs in clinical trials: Why use them, and how to run and report them

*BMC Medicine* 2018; 16:29

Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): A pragmatic, randomised controlled, superiority trial

*Lancet Psychiatry* 2018; 5(2):119-133

Training nurses in a competency framework to support adults with epilepsy and intellectual disability: The EpAID cluster RCT

*Health Technology Assessment* 2018; 22(10):1-104

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements

*Statistics in Medicine* 2017; 36(29):4616-4626

Group sequential designs for stepped-wedge cluster randomised trials

*Clinical Trials* 2017; 14(5):501-517

The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI

*European Radiology* 2017; 27(12):5236-5243

Imaging biomarker roadmap for cancer studies

*Nature Reviews Clinical Oncology* 2017; 14(3):169-186